Twin Tree Management
VRTX icon

Twin Tree Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Twin Tree Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Sell
2,700
-24,100
-90% -$10.7M 0.03% 730
2026
Q1 		$12M Buy
26,800
+1,400
+6% +$653K 0.25% 64
2025
Q4 		$11.5M Sell
25,400
-21,200
-45% -$9.14M 0.1% 252
2025
Q3 		$18.3M Buy
46,600
+12,500
+37% +$5.22M 0.08% 314
2025
Q2 		$15.2M Sell
34,100
-10,000
-23% -$4.61M 0.03% 588
2025
Q1 		$21.4M Buy
44,100
+38,800
+732% +$18.1M 0.04% 409
2024
Q4 		$2.13M Buy
+5,300
New +$2.46M ﹤0.01% 1132
2024
Q2 		– Sell
-122,200
Closed -$51.1M – 1680
2024
Q1 		$51.1M Sell
122,200
-60,200
-33% -$25.4M 0.11% 175
2023
Q4 		$74.2M Buy
+182,400
New +$67.4M 0.14% 135
2023
Q1 		– Sell
-47,300
Closed -$13.7M – 1613
2022
Q4 		$13.7M Sell
47,300
-100
-0.2% -$30.5K 0.03% 488
2022
Q3 		$13.7M Sell
47,400
-7,400
-14% -$2.13M 0.03% 473
2022
Q2 		$15.4M Buy
54,800
+5,400
+11% +$1.45M 0.02% 502
2022
Q1 		$12.9M Sell
49,400
-20,100
-29% -$4.77M 0.02% 622
2021
Q4 		$15.3M Buy
+69,500
New +$13.5M 0.03% 496
2020
Q1 		– Sell
-4,300
Closed -$941K – 1642
2019
Q4 		$941K Buy
+4,300
New +$870K ﹤0.01% 872
2019
Q2 		– Sell
-3,500
Closed -$644K – 1576
2019
Q1 		$644K Buy
+3,500
New +$646K ﹤0.01% 915
2018
Q4 		– Sell
-19,000
Closed -$3.66M – 1528
2018
Q3 		$3.66M Buy
+19,000
New +$3.38M 0.02% 459
2018
Q1 		– Sell
-101,600
Closed -$15.2M – 1324
2017
Q4 		$15.2M Sell
101,600
-56,000
-36% -$8.29M 0.11% 151
2017
Q3 		$24M Buy
+157,600
New +$23.7M 0.19% 107

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Twin Tree Management's VRTX Position: Q2 2026 in Review

Twin Tree Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 7,769 shares — an estimated $3.44M sold.

Twin Tree Management first reported a position in VRTX in Q3 2017 and held it in 26 quarters. The position peaked at $52.8M in Q4 2023. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Twin Tree Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Tree Management sold 7,769 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.44M.
  • Twin Tree Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 26 quarters.
  • Twin Tree Management's Vertex Pharmaceuticals position peaked at $52.8M in Q4 2023.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Twin Tree Management's 13F filing for Q2 2026, filed 12 Aug 2026.